E. G. Sazhina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
E. G. Sazhina has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Olga N. Egorova
V.A. Nasonova Research Institute of Rheumatology
3 shared publications - Boris S. Belov
V.A. Nasonova Research Institute of Rheumatology
2 shared publications - E. V. Zemerova
Budget institution of the Khanty-Mansiysk Autonomous Okrug Ugra “District Clinical Hospital
2 shared publications - Inna B. Bashkova
Chuvash State University named after I.N. Ulyanov; Federal Center for Traumatology, Orthopedics and Arthroplasty (Cheboksary)
2 shared publications - L. V. Masneva
St. Joasaph Belgorod Regional Clinical Hospital
2 shared publications - Oxana Zhirnova
Kazakh National Research Technical University named after K.I. Satpayev, Almaty, Republic of Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 15 June 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (3) , 78-84
Peculiar features of intravenous immunoglobulins application in rheumatic diseases
Intravenous immunoglobulins (IVIG) are the most commonly used immunobiological agents produced from donor blood. They were first used in the mid-twentieth century for the treatment of primary immunodeficiencies. Later, they were successfully used to treat a variety of autoimmune, inflammatory and other diseases. There are currently a growing number of basic and clinical studies looking at the mechanism of action and efficacy of different doses of IVIG. At the same time, much remains unclear, contradictory, and some data are mutually exclusive.
- 15 June 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (3) , 78-84
Open AccessPeculiar features of intravenous immunoglobulins application in rheumatic diseases
Intravenous immunoglobulins (IVIG) are the most commonly used immunobiological agents produced from donor blood. They were first used in the mid-twentieth century for the treatment of primary immunodeficiencies. Later, they were successfully used to treat a variety of autoimmune, inflammatory and other diseases. There are currently a growing number of basic and clinical studies looking at the mechanism of action and efficacy of different doses of IVIG. At the same time, much remains unclear, contradictory, and some data are mutually exclusive.
- 23 April 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (6) , 2145-2152
Combination of Sjögren’s syndrome and anti-Ku syndrome complicated by the development of mucosa-associated lymphoid tissue lymphoma: case review and systematic review of the literature
The frequency of antibodies to Ku varies in various autoimmune diseases. In 2019, Spielmann et al. identified two types of anti-Ku syndrome based on a hierarchical clustering analysis. Sjögren’s syndrome occurs both in the first type of anti-Ku syndrome and in the second type. Despite the fact that increased tissue expression of Ku proteins was noted in lymphocytic cells with focal sialoadenitis of the minor salivary glands in patients with primary Sjogren’s syndrome, only 49 cases of a combination of anti-Ku antibodies and manifestations of Sjogren’s syndrome have been described in the literature. Some researchers examined patients for the presence of Sjogren’s syndrome only if they had anti-Ro or anti-La antibodies, although in the literature, there are descriptions of Sjogren’s syndrome in the presence of only isolated anti-Ku antibodies, as in our case. Literature data on glandular and extraglandular manifestations of Sjögren’s syndrome in anti-Ku-positive patients are limited. Below, we present the first case of Sjögren’s syndrome in combination with the first type of anti-Ku syndrome complicated by the development of mucosa-associated lymphoid tissue (MALT) lymphoma. The article also provides a systematic review of the literature on the association of Sjögren’s syndrome with anti-Ku antibodies.
- 23 April 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (6) , 2145-2152
Combination of Sjögren’s syndrome and anti-Ku syndrome complicated by the development of mucosa-associated lymphoid tissue lymphoma: case review and systematic review of the literature
The frequency of antibodies to Ku varies in various autoimmune diseases. In 2019, Spielmann et al. identified two types of anti-Ku syndrome based on a hierarchical clustering analysis. Sjögren’s syndrome occurs both in the first type of anti-Ku syndrome and in the second type. Despite the fact that increased tissue expression of Ku proteins was noted in lymphocytic cells with focal sialoadenitis of the minor salivary glands in patients with primary Sjogren’s syndrome, only 49 cases of a combination of anti-Ku antibodies and manifestations of Sjogren’s syndrome have been described in the literature. Some researchers examined patients for the presence of Sjogren’s syndrome only if they had anti-Ro or anti-La antibodies, although in the literature, there are descriptions of Sjogren’s syndrome in the presence of only isolated anti-Ku antibodies, as in our case. Literature data on glandular and extraglandular manifestations of Sjögren’s syndrome in anti-Ku-positive patients are limited. Below, we present the first case of Sjögren’s syndrome in combination with the first type of anti-Ku syndrome complicated by the development of mucosa-associated lymphoid tissue (MALT) lymphoma. The article also provides a systematic review of the literature on the association of Sjögren’s syndrome with anti-Ku antibodies.
- Open Access
- 20 October 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (5) , 108-113
Use of botulinum toxin type A in rheumatic diseases
The article presents an analysis of modern data on the antinociceptive effectiveness of botulinum toxin type A (BTA) in rheumatic diseases (RD). The prospects for the use of BTA in the treatment of pain in different RDs are discussed. We searched for publications in the Medline, Pubmed, Cochrane Library databases. Analysis of literature data has shown that BTA can become an additional method of pain management in many RDs.
- 20 October 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (5) , 108-113
Open AccessUse of botulinum toxin type A in rheumatic diseases
The article presents an analysis of modern data on the antinociceptive effectiveness of botulinum toxin type A (BTA) in rheumatic diseases (RD). The prospects for the use of BTA in the treatment of pain in different RDs are discussed. We searched for publications in the Medline, Pubmed, Cochrane Library databases. Analysis of literature data has shown that BTA can become an additional method of pain management in many RDs.
- Open Access
- 24 June 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (3) , 75-80
Comorbidity in patients with lobular panniculitis-lipodermatosclerosis
Lipodermatosclerosis (LDS) is one of the variants of lobular panniculitis. The onset of LDS falls on the age of 50–60 years, when many patients already have comorbid pathology requiring complex therapy, which affects the course, the choice of treatment and prognosis of LDS, as well as the quality of life.Objective: to study the structure and frequency of comorbid conditions in patients with LDS.Patients and methods. 53 patients (3 men and 50 women), 18–80 years old, with a verified diagnosis of LDS were included, all of them had an average follow up of 10 years (they were observed in the V.A. Nasonova Research Institute of Rheumatology). The duration of the disease ranged from 2 weeks to 20 years. During clinical examination, the localization, prevalence, color and number of affected skin areas and sub cutaneous fat were determined. The intensity of pain on palpation of the node was assessed using a visual analogue scale (VAS). Laboratory and instrumental research included: blood and urine tests, computed tomography of the chest and ultrasound Doppler of the lower extremities with registration of the linear blood flow velocity in the affected veins (femoral, popliteal, posterior tibial, foot veins). Clinical, laboratory and instrumental examination of patients was carried out 2 times a year. The CIRS and Charlson indices were used to assess the relationship between comorbid pathology and LDS.Results and discussion. Most patients (60.3%) were women with increased body weight (91.5±21.8 kg). Depending on the duration of the disease, the main variants of the LDS course were: acute (6 months). Skin changes were associated with polyarthralgia (34%) and/or myalgia (22.6%), mainly on the side of the affected limb. In 16 patients, an increase in ESR, on average 23.8±7.8 mm per hour, was detected, in 7 patients, including 4 with an acute course of LDS, – more than a threefold increase in the level of CRP. No comorbid diseases had 17 patients, 64.7% of them were under 50 years and had an acute course of LDS (p=0.02). In 68% of patients, mainly with chronic LDS, the following concomitant diseases was recorded: chronic venous insufficiency (CVI; in 67.9%); exogenous constitutional obesity (in 60.3%); rheumatic diseases (45.2%), including osteoarthritis (75%), rheumatoid arthritis (17%), antiphospholipid syndrome (8%), and arterial hypertension (39.6%). Most patients had 1 concomitant disease, and almost one fifth of patients had 2 concomitant diseases. The proportion of patients with 3 comorbid pathologies was 11.1%, with 4 – 8.3% and with 5 – 5.5%. When assessing the Charlson index, a 10-year survival rate of >90% (index values from 0 to 2 points) was observed in 66% of patients, 53–77% (3–4 points) – in 26.4% and Conclusion. In patients with LDS, a high incidence of comorbid pathology was noted. Interdisciplinary approach with interaction between doctors of different specialties is required for treatment of these patients.
- 24 June 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (3) , 75-80
Open AccessComorbidity in patients with lobular panniculitis-lipodermatosclerosis
Lipodermatosclerosis (LDS) is one of the variants of lobular panniculitis. The onset of LDS falls on the age of 50–60 years, when many patients already have comorbid pathology requiring complex therapy, which affects the course, the choice of treatment and prognosis of LDS, as well as the quality of life.Objective: to study the structure and frequency of comorbid conditions in patients with LDS.Patients and methods. 53 patients (3 men and 50 women), 18–80 years old, with a verified diagnosis of LDS were included, all of them had an average follow up of 10 years (they were observed in the V.A. Nasonova Research Institute of Rheumatology). The duration of the disease ranged from 2 weeks to 20 years. During clinical examination, the localization, prevalence, color and number of affected skin areas and sub cutaneous fat were determined. The intensity of pain on palpation of the node was assessed using a visual analogue scale (VAS). Laboratory and instrumental research included: blood and urine tests, computed tomography of the chest and ultrasound Doppler of the lower extremities with registration of the linear blood flow velocity in the affected veins (femoral, popliteal, posterior tibial, foot veins). Clinical, laboratory and instrumental examination of patients was carried out 2 times a year. The CIRS and Charlson indices were used to assess the relationship between comorbid pathology and LDS.Results and discussion. Most patients (60.3%) were women with increased body weight (91.5±21.8 kg). Depending on the duration of the disease, the main variants of the LDS course were: acute (6 months). Skin changes were associated with polyarthralgia (34%) and/or myalgia (22.6%), mainly on the side of the affected limb. In 16 patients, an increase in ESR, on average 23.8±7.8 mm per hour, was detected, in 7 patients, including 4 with an acute course of LDS, – more than a threefold increase in the level of CRP. No comorbid diseases had 17 patients, 64.7% of them were under 50 years and had an acute course of LDS (p=0.02). In 68% of patients, mainly with chronic LDS, the following concomitant diseases was recorded: chronic venous insufficiency (CVI; in 67.9%); exogenous constitutional obesity (in 60.3%); rheumatic diseases (45.2%), including osteoarthritis (75%), rheumatoid arthritis (17%), antiphospholipid syndrome (8%), and arterial hypertension (39.6%). Most patients had 1 concomitant disease, and almost one fifth of patients had 2 concomitant diseases. The proportion of patients with 3 comorbid pathologies was 11.1%, with 4 – 8.3% and with 5 – 5.5%. When assessing the Charlson index, a 10-year survival rate of >90% (index values from 0 to 2 points) was observed in 66% of patients, 53–77% (3–4 points) – in 26.4% and Conclusion. In patients with LDS, a high incidence of comorbid pathology was noted. Interdisciplinary approach with interaction between doctors of different specialties is required for treatment of these patients.
- Open Access
- 17 June 2014
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 52 (2) , 147-158-147
RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA)
В 2013 г. в России официально зарегистрированы показания для применения моноклональных антител к В-лимфо- цитам (ритуксимаб, РТМ) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматиче- скими антителами (АНЦА-СВ). Данное сообщение представляет предварительные результаты Российского регист- ра применения РТМ при аутоиммунных заболеваниях (НОРМА), включившего 50 больных АНЦА-СВ, получавших лечение в 14 городах Российской Федерации. У 25 из 50 (50%) пациентов проводили повторные курсы РТМ. В условиях реальной отечественной клинической практики РТМ проявил высокую эффективность у больных АНЦА-СВ с хорошим профилем безопасности лечения. Среди 25 пациентов, наблюдавшихся более 12 мес, ремис- сия была достигнута в 92% случаев, в 8% наблюдалось снижение активности АНЦА-СВ. Эффективность РТМ воз- растала при использовании повторных курсов, при этом отмечено, что положительные результаты могут быть полу- чены при назначении повторных курсов РТМ в редуцированных дозах (500–1000 мг). Назначение повторных кур- сов в первую очередь потребовалось больным гранулематозом с полиангиитом с поражением легких. Требуется осторожность при сочетании лечения РТМ с цитостатиками (прежде всего с циклофосфаном) в связи с опасностью вторичного иммунодефицитного состояния и инфекционных нежелательных реакций (НР), которые были наиболее частыми серьезными НР (12%) у больных АНЦА-СВ.
- 17 June 2014
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 52 (2) , 147-158-147
Open AccessRUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA)
В 2013 г. в России официально зарегистрированы показания для применения моноклональных антител к В-лимфо- цитам (ритуксимаб, РТМ) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматиче- скими антителами (АНЦА-СВ). Данное сообщение представляет предварительные результаты Российского регист- ра применения РТМ при аутоиммунных заболеваниях (НОРМА), включившего 50 больных АНЦА-СВ, получавших лечение в 14 городах Российской Федерации. У 25 из 50 (50%) пациентов проводили повторные курсы РТМ. В условиях реальной отечественной клинической практики РТМ проявил высокую эффективность у больных АНЦА-СВ с хорошим профилем безопасности лечения. Среди 25 пациентов, наблюдавшихся более 12 мес, ремис- сия была достигнута в 92% случаев, в 8% наблюдалось снижение активности АНЦА-СВ. Эффективность РТМ воз- растала при использовании повторных курсов, при этом отмечено, что положительные результаты могут быть полу- чены при назначении повторных курсов РТМ в редуцированных дозах (500–1000 мг). Назначение повторных кур- сов в первую очередь потребовалось больным гранулематозом с полиангиитом с поражением легких. Требуется осторожность при сочетании лечения РТМ с цитостатиками (прежде всего с циклофосфаном) в связи с опасностью вторичного иммунодефицитного состояния и инфекционных нежелательных реакций (НР), которые были наиболее частыми серьезными НР (12%) у больных АНЦА-СВ.
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 1003
AB0598 Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from A Russian Registry (NORMA)
Background Rituximab (RTX) therapy is a treatment option in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Objectives Analysis of safety and efficacy of RTX in patients with ANCA-associated vasculitis treated in fourteen Russian clinical centers. Methods In 2011, Nasonova V.A. Research Institute of Rheumatology and Association of Rheumatologists of Russia created the NORMA project, a multicenter study whose objective is to gather information concerning the use of RTX in adult patients with systemic autoimmune diseases. Results 50 patients with ANCA-associated vasculitis treated with RTX are included in the NORMA registry (26 women and 24 men, mean age 40±15 years), including 35 patients with granulomatosis with polyangiitis, 13 with microscopic polyangiitis, 2 with eosinophilic granulomatosis with polyangiitis. 39 patients were cANCA/PR3 positive and 11 pANCA/MPO positive. 34% of patients had refractory ANCA-associated vasculitis, 36% high activity and/or signs of poor prognosis and 28% intolerance of standard agents. 25/50 patients were re-treatment at low-dose RTX (≤1000 mg) for partial responses/relapses (70%) or to maintain remission (30%). A total of 46 RTX subsequent cycles were completed, intervals between cycles averaged 6.4 months (range 4.5-11.3). Among 25 patients followed for more than 12 months, 23 complete and 2 partial responses were observed. Table 1 shows Birmingham vasculitis activity score (BVAS), CD19+ B-cells in peripheral blood and serum IgG levels at enrolment and after RTX treatment. Re-treatment was effective in controlling disease activity and did not result in progressive reduction in IgG. Ten patients (20%) had serious adverse events (including 6 infections and 3 neutropenia), all received a single cycle of RTX. Five patients died, two due to pneumonia and late onset neutropenia, two due to acute pulmonary embolism and one patient due to refractory vasculitis and pneumonia. BVAS, CD19+ B-cells and IgG levels at baseline, 3 and 6 months after each cycle of RTX Conclusions This uncontrolled observational study shows good tolerance and clinical efficacy of RTX in patients with ANCA-associated vasculitis and suggest, that low-dose RTX for the re-treatment is also effective. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1960
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 1003
AB0598 Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from A Russian Registry (NORMA)
Background Rituximab (RTX) therapy is a treatment option in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Objectives Analysis of safety and efficacy of RTX in patients with ANCA-associated vasculitis treated in fourteen Russian clinical centers. Methods In 2011, Nasonova V.A. Research Institute of Rheumatology and Association of Rheumatologists of Russia created the NORMA project, a multicenter study whose objective is to gather information concerning the use of RTX in adult patients with systemic autoimmune diseases. Results 50 patients with ANCA-associated vasculitis treated with RTX are included in the NORMA registry (26 women and 24 men, mean age 40±15 years), including 35 patients with granulomatosis with polyangiitis, 13 with microscopic polyangiitis, 2 with eosinophilic granulomatosis with polyangiitis. 39 patients were cANCA/PR3 positive and 11 pANCA/MPO positive. 34% of patients had refractory ANCA-associated vasculitis, 36% high activity and/or signs of poor prognosis and 28% intolerance of standard agents. 25/50 patients were re-treatment at low-dose RTX (≤1000 mg) for partial responses/relapses (70%) or to maintain remission (30%). A total of 46 RTX subsequent cycles were completed, intervals between cycles averaged 6.4 months (range 4.5-11.3). Among 25 patients followed for more than 12 months, 23 complete and 2 partial responses were observed. Table 1 shows Birmingham vasculitis activity score (BVAS), CD19+ B-cells in peripheral blood and serum IgG levels at enrolment and after RTX treatment. Re-treatment was effective in controlling disease activity and did not result in progressive reduction in IgG. Ten patients (20%) had serious adverse events (including 6 infections and 3 neutropenia), all received a single cycle of RTX. Five patients died, two due to pneumonia and late onset neutropenia, two due to acute pulmonary embolism and one patient due to refractory vasculitis and pneumonia. BVAS, CD19+ B-cells and IgG levels at baseline, 3 and 6 months after each cycle of RTX Conclusions This uncontrolled observational study shows good tolerance and clinical efficacy of RTX in patients with ANCA-associated vasculitis and suggest, that low-dose RTX for the re-treatment is also effective. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1960